GSK plc (GSK,GSK.L,GS71.DE) has entered an agreement to acquire 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of protein-based therapeutics. GSK will acquire 100% of the equity of 35Pharma Inc. for $950 million, payable in cash at closing.
The acquisition includes HS235, an investigational medicine that has completed phase I healthy volunteer clinical trials with studies to start imminently in pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction.
At last close, GSK shares were trading at 2,201.00 pence, down 0.23%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.